Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults
Top Cited Papers
Open Access
- 1 March 2007
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 64 (3) , 343-349
- https://doi.org/10.1001/archneur.64.3.noc60123
Abstract
Without truly effective therapies, Alzheimer disease (AD) will soon become a public health crisis. Biological markers are essential to aid in the development of disease-modifying therapies and identify individuals at high risk or in the earliest clinical stages. Alzheimer disease pathologic abnormalities (amyloid plaques, neurofibrillary tangles) appear to begin 10 to 20 years before cognitive symptoms or significant neuronal loss.1-5 Thus, it is critical to identify affected individuals while they are still cognitively normal (preclinical AD), prior to overt synaptic and neuronal loss, so new therapies have a chance to preserve normal brain function.Keywords
This publication has 8 references indexed in Scilit:
- Neuropathologic Substrate of Mild Cognitive ImpairmentArchives of Neurology, 2006
- Antecedent Biomarkers of Alzheimer’s Disease: The Adult Children StudyJournal of Geriatric Psychiatry and Neurology, 2005
- In VivoAssessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-LifeJournal of Neuroscience, 2003
- Head Circumference, Education and Risk of Dementia: Findings from the Nun StudyJournal of Clinical and Experimental Neuropsychology, 2003
- Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer diseaseNeuroscience Letters, 2001
- Gender differences in the incidence of AD and vascular dementiaNeurology, 1999
- Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s DiseaseJournal of Neuroscience, 1996
- The Clinical Dementia Rating (CDR)Neurology, 1993